Strikingly, inhibition of HH/GLI signaling in the tumor stroma of pancreatic cancer led to enhanced tumor growth rather than a therapeutic effect, reflecting the discouraging outcome of anti-HH trials in pancreatic cancer patients [127–129]. Here, GLI1 is linked to neoplasm.